Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy

Treatment with VK0214 led to Significant Reductions in Plasma and Tissue Levels of VLCFAs

Good news. ABCD2 making steady progress...

ir.vikingtherapeutics.com/2...

1 Reply

oldestnewest
  • Pretty cool. Thanks so much for sharing!

You may also like...